Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.42 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3377543 | 0.87 | CA1 (0.57) | ERN1CA1CA2CA12CA7 | |
| SCHEMBL29931004 | 0.85 | CA12 (0.47) | CA1CA2CA12CA7CA9 | |
| SCHEMBL16008609 | 0.85 | CA12 (0.47) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1070351 | 0.83 | CA12 (0.61) | CA1CA2CA12CA7CA9 | |
| SCHEMBL26617428 | 0.81 | CA1 (0.50) | ERN1CA1CA2CA12CA7 | |
| SCHEMBL7836382 | 0.81 | CA1 (0.71) | ERN1CA1CA2CA12CA7 | |
| SCHEMBL5739889 | 0.79 | CA1 (0.48) | ERN1CA1CA2CA12CA7 | |
| SCHEMBL15093769 | 0.79 | CA1 (0.48) | ERN1CA1CA2CA12CA7 | |
| SCHEMBL16009131 | 0.79 | ERN1 (0.59) | ERN1CA1CA2CA12CA7 | |
| SCHEMBL4467342 | 0.79 | CA1 (0.44) | ERN1CA1CA2CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035354-A1 | PIPERIDINEDIONE DERIVATIVES | INNOCURE THERAPEUTICS, INC. (KR) | 2026-02-05 | — | — | US | disclosed |
| EP-4640686-A1 | DEGRADER FOR DEGRADING BRD PROTEIN AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Innocure Therapeutics, Inc. (KR) | 2025-10-29 | — | — | EP | disclosed |
| EP-4624466-A1 | DEGRADER FOR DECOMPOSING CMET PROTEIN, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Innocure Therapeutics, Inc. (KR) | 2025-10-01 | — | — | EP | disclosed |
| EP-4624472-A1 | DEGRADER INCLUDING NOVEL C-MET PROTEIN LIGAND AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Innocure Therapeutics, Inc. (KR) | 2025-10-01 | — | — | EP | disclosed |
| US-12384756-B2 | Piperidinedione derivatives | INNOCURE THERAPEUTICS, INC. (KR) | 2025-08-12 | — | — | US | disclosed |
| WO-2024112119-A1 | DEGRADER FOR DECOMPOSING CMET PROTEIN, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 이노큐어테라퓨틱스 | 2024-05-30 | — | — | WO | disclosed |
| WO-2024112119-A1 | DEGRADER FOR DECOMPOSING CMET PROTEIN, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 이노큐어테라퓨틱스 | 2024-05-30 | — | — | WO | disclosed |
| WO-2024112122-A1 | DEGRADER FOR DEGRADING BRD PROTEIN AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 주식회사 이노큐어테라퓨틱스 | 2024-05-30 | — | — | WO | disclosed |
| WO-2024112120-A1 | DEGRADER INCLUDING NOVEL C-MET PROTEIN LIGAND AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | 주식회사 이노큐어테라퓨틱스 | 2024-05-30 | — | — | WO | disclosed |
| WO-2024112120-A1 | DEGRADER INCLUDING NOVEL C-MET PROTEIN LIGAND AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | 주식회사 이노큐어테라퓨틱스 | 2024-05-30 | — | — | WO | disclosed |
| US-20140256734-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-11 | — | — | US | disclosed |
| US-20140256734-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-11 | — | — | US | disclosed |
| EP-2641907-A1 | Preparation of modulators of 5-HT receptors | AbbVie Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| EP-2432783-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LAB (US) | 2013-05-01 | — | — | EP | disclosed |
| EP-2571353-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2432783-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2011146089-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2010135560-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298292-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035354-A1 | PIPERIDINEDIONE DERIVATIVES | CRBN, PSMC1, PSME3 | ERN1 1390/4885CA1 2480/4885CA2 2544/4885 |
| US-20100298292-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | ERN1 4806/4885CA1 3888/4885CA2 2905/4885 |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | ERN1 4806/4885CA1 3888/4885CA2 2905/4885 |
| US-20140256734-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | BTK, LCK, TYK2 | ERN1 1302/4885CA1 4734/4885CA2 4207/4885 |
| US-12384756-B2 | Piperidinedione derivatives | CRBN, CUL1, PSMB10 | ERN1 1842/4885CA1 3035/4885CA2 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.